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LABORATORY INVESTIGATION
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Interleukin.113 stimulates human mesangial cells to synthesize and
release interleukins-6 and -8. Interleukin-l/3 (IL-1f3) and tumor necrosis
factor (TNF) have been reported to stimulate human mesangial cells
(HMC) to proliferate and synthesize eicosanoids. We have examined
whether they also induce HMC to release cytokines. In this study we
show that both IL-I and TNF stimulate HMC to release IL-6 and IL-8.
Cycling and quiescent HMC were stimulated with various concentra-
tions of either recombinant IL-l/3 or TNF for 1 to 24 hours. IL-lp at
doses as low as 6 pglml stimulated mesangial cells to synthesize mRNA
for both IL-6 and IL-8 as assessed by Northern analysis; mRNA for
tubulin remained constant, which demonstrated a specific increase in
mRNA. Secretion of IL-6 and IL-8 into the culture medium increased
(4.5 to 18 nglml and 4 to 40 ng/ml, respectively) measured by ELISAs.
TNF had similar effects but only in high concentrations (> 100 nglml).
IL-lp did not stimulate cells to proliferate, as measured by 3H thymi-
dine incorporation. TNF caused proliferation but only in concentrations
over 100 ng/ml. We conclude that IL- 1/3 is a potent stimulator of human
mesangial cell production of IL-6 and IL-8, both of which may influence
injury in nephritis. TNF also stimulates mesangial cells but only in
pharmacological doses.
The existence of the mesangium in the axial region of
glomeruli was first recognized by Zimmermann [1] and charac-
terized by Latta, Maunsbach and Madden [2], who suggested
that it provided support for glomerular capillaries. It is now
known to have a much more dynamic role that includes the
clearance of macromolecules and the control of glomerular
filtration rate [3, 4]. The normal mesangium contains two
distinct cell types embedded in extracellular matrix. Intrinsic
mesangial cells have many of the characteristics of vascular
smooth muscle and are presumed to secrete matrix. The re-
maining cells are resident leucocytes, most of which are prob-
ably derived from macrophages. The mesangium in glomerulo-
nephritis is infiltrated with neutrophils and monocytes, intrinsic
mesangial cells proliferate and there is increased deposition of
matrix. Clearly the relations between these processes are
crucial to the proper understanding of nephritis.
Recent studies have emphasized the importance of cytokines
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and polypeptide growth factors in controlling the intensity of
inflammation, and the tendency to scarring [5—7]. Macrophages
are an uniquely rich source of these factors [8] and when
activated release large amounts of tumor necrosis factor (TNF),
interleukins-l, -6 and -8, as well as growth factors such as
platelet derived growth factor (PDGF) [9] and transforming
growth factor-p [10]. These are part of an integrated network
whose complexities are only just beginning to be understood
[11]. For example, both TNF and IL-l activate inflammatory
cells and stimulate them to synthesize other cytokines, includ-
ing IL-8 a chemotactic factor for neutrophils and lymphocytes.
This also provokes the release of IL-6 [12, 13] and TGF-/3 [14]
which down-regulate (deactivate) macrophages, and limit the
capacity for further TNF synthesis release.
TNF and IL-i are released from nephritic glomeruli cultured
in vitro [15, 16], and studies using anti-cytokine antibodies have
established that TNF [17] and IL-i (Karkar and Rees, manu-
script in preparation) modulate the severity of inflammation in
the heterologous phase of nephrotoxic serum nephritis. Re-
cently TGF-f3 has been shown to mediate increased matrix
synthesis in antibody-induced mesangial proliferative nephritis
in rats [181, and this was down-regulated by treatment with
anti-TGF-/3 antibodies [19]. Infiltrating monocytes are the most
obvious source of glomerular cytokines in nephritis, but intrin-
sic mesangial cells probably produce a limited range of cyto-
kines, albeit in smaller quantities. Cultured rat mesangial cells
have been reported to produce TNF, IL-i, IL-6, and GM-CSF
[20—25], although the methods used to detect them have not
always been specific. Mesangial cells also respond to cytokines;
TNF, IL-i and IL-6 have been reported to stimulate rat
mesangial cells to proliferate and to induce a range of other
responses, including increased matrix synthesis [26], produc-
tion of cyclic AMP [27], prostaglandins and an increase in
protein kinase activity [28]. There are fewer data on human
mesangial cells but they proliferate in response to macrophage
purified IL-i [26], and respond to recombinant IL-i /3 with
increased eicosanoid [29] and oxygen radical production [30].
There are difficulties in determining the relevance of in vitro
studies to events occurring in vivo, and these are particularly
severe in the case of cytokines and mesangial cells. For
example, contamination of cultures with small numbers of
macrophages in early passages could suggest spuriously that a
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particular cytokine is produced by mesangial cells; cytokines
used in many of the early studies were purified from macro-
phages and it is now known that such preparations often contain
more than one cytokine [31]; many of the assays used to
quantify cytokines are less specific than originally believed; and
lastly, unrealistically high concentrations of cytokines have
often been used.
The present study was designed to investigate the effects of
two pro-inflammatory cytokines, TNF and IL-1f3, on cultured
human mesangial cells. In particular, we studied their effect on
the production of IL-8, a powerful chemotactic factor which
could be important for attracting neutrophils to the inflamed
glomerulus, and IL-6 which is known to have broad modulatory
effects on immunity, and inflammation [32, 331. We have also
examined the effect of TNF and IL-113 on mesangial cell
proliferation. The results show that human recombinant IL-1f3
is a powerful stimulant for mesangial cell cytokine synthesis
and the TNF has the same effect, but only at high concentra-
tions. Neither TNF nor IL-1f3 induce mesangial cell prolifera-
tion at clinically relevant concentrations, although TNF does at
pharmacological doses.
Methods
Reagents
Human recombinant IL-l/3 (hrIL-1f3) was obtained from Dr.
Alan Shaw (Glaxo Institute of Molecular Biology) and had a
specific activity of 2.5 x iO U/mg protein using the lymphocyte
activation assay [34]. Human recombinant TNF was obtained
from Dr. V. Schwendemann (Knoll AG, Ludwigshafen, Ger-
many) and had a specific activity of 9.6 X 106 U/mg using the
L929 cell cytotoxicity assay [35]. Both reagents were made in
Escherichia coli and were free from endotoxin contamination
using the Limulus amoebocyte lysate assay. This assay was
performed using a test kit (Kabi Vitrim Ltd., Uxbridge, UK)
with a limit of detection of 5 pg/ml. The cDNA probes for
IL-l/3, IL-6 and TNF were also supplied by Dr. Shaw. The
eDNA probe for human tubulin a 1.6 Kb insert subcloned into
pSP64 plasmid was used as a control [361.
Culture of human mesangial cells
Mesangial cells were cultured as previously described [37].
Briefly, glomeruli were purified from the normal cortex ob-
tained from kidneys removed because of renal cell carcinoma.
The cortex was diced and pushed through a set of sieves (150 ,
250 /h, 106 and 63 ) to yield decapsulated glomeruli with little
tubular contamination. The purified glomeruli were treated
collagenase Type I (Sigma, Poole, UK) at 1 mg/ml for 20
minutes at 37°C, to loosen cell attachment to the matrix. The
resulting glomerular fragments were plated on fibronectin
coated, 6-well cluster plates, and grown in RPM1 1640 medium
(Gibco Ltd, Paisley, UK) supplemented with 10% fetal calf
serum, 2 mr'i L-glutamine and an insulin, selenium, transferrin
growth supplement (25 mg insulin from bovine pancreas, 25 mg
human transferrin and 25 jg sodium selenite; Sigma) used in
accordance with manufacturer's instructions. Penicillin (100
IU/ml) and streptomycin (100 sgIml) were also added routinely.
All cultures were carried out in humidified air with 5% CO2 at
37°C. The cells were removed when confluent, using trypsin/
EDTA and subcultured in 75 sq cm flasks (Linbro, Flow Labs,
Rickmansworth, UK) and later in 150 sq cm flasks. The cells
used in these experiments were between passage numbers 4 and
8.
Identification of mesangial cells
The purity of mesangial cell cultures was assessed using
markers that we have previously shown to discriminate be-
tween various glomerular cell types [37]. Samples of cells were
subcultured on fibronectin-coated 13 mm glass coverslips
placed in 24-well cluster plates and grown in standard medium.
Selected coverslips were removed after 48 hours, washed in
phosphate buffered saline (PBS), air dried and fixed in ethanol
at 4°C for five minutes. The cells were stained for actin
filaments using a specific anti-smooth muscle actin monoclonal
antibody (Sigma) and for cytokeratin using a monoclonal anti-
body (Becton-Dickinson, Oxford, UK). Both monoclonal anti-
bodies were detected using a second layer fluorescein labelled
anti-mouse Ig antibody (Dako, High Wycombe, UK). The cells
were then washed and mounted in citifluor 95% glycerol (Citi-
fluor, University of London, UK). Other coverslips were used
to test for uptake of acetylated low density lipoprotein (Ac.
LDL), an endothelial cell marker but which is also taken up by
macrophages. These coverslips were incubated with dioctade-
cyl tetramethyl-indo-carbocyanin perchlorate (Dii) labelled
Ac.LDL (Biogenesis, Bournemouth, UK) for four hours. After
washing, they were fixed in 1% paraformaldehyde for five
minutes at room temperature and examined by ultraviolet
microscopy.
The cells were also examined by electron microscopy. A cell
suspension was fixed in 2% glutaraldehyde for two hours. Mter
washing in phosphate buffer the cells were osmicated and
dehydrated in a series of graded alcohols. Between all solution
changes cells were spun at 2000 rpm, the supernatant removed,
and the pellet resuspended in the next solution. The final pellet
was embedded in Taab resin and polymerized at 60°C over-
night. Sections of 1 im were cut and stained with Toludine blue
for observation at light microscopy level. Ultrathin sections of
approximately 100 nm, were collected on nickel grids and
stained with uranyl acetate and lead citrate, for observation on
a Philips CM-b electron microscope.
Proliferation assays
Cellular proliferation was assessed indirectly by incorpora-
tion of tritium (3H) labelled thymidine into newly synthesized
DNA. Cells were plated into 96-well flat-bottomed cluster
plates at a density of 1 x l0 cells per well, and cultured for 48
hours before incubating in culture medium with 0.25% platelet-
poor human plasma (PPP) for 48 hours to make them quiescent.
The cells were then incubated for 24 hours with hrIL-lp or
hrTNF either in quiescing medium containing 0.25% PPP or in
full growth medium containing 10% fetal calf serum. Then they
were pulsed with 3H thymidine (lbs Ci/well) and cultured for a
further 24 hours. The cells were removed using trypsin/EDTA
and harvested onto filters using a titertek cell harvester (Flow
Labs, Rickmansworth, UK). Incorporated 3H was measured by
placing filters into vials containing scintillation fluid and count-
ing on a liquid scintillation counter (Beckman). The results of
three replicates for each concentration of cytokine added were
recorded as disintegrations per minute (DPM). This enabled us
to assess the effects of the cytokines both on quiescent and
proliferating cells.
Northern analysis
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Confluent cells in 150 sq cm tissue culture flasks were
quiesced for 48 hours to synchronize the cell cycle, and again
the cytokines were added in fresh serum-free medium contain-
ing 0.25% PPP or full growth medium. They were harvested at
various times (most commonly after 3 hr) in guanidinium
thiocyanate solution, and the total cellular RNA was purified by
cesium chloride density gradient ultra-centrifugation [38]. Au-
quots of 30 tg of total cellular RNA from each mesangial cell
sample were run in 1% agarose formaldehyde gels and trans-
ferred to Genescreen plusTM (New England Nuclear, Boston,
Massachusetts, USA) by capillary blot using 10 X SSC solution(lx SSC = 15 mst trisodium citrate, 150 m sodium chloride).
The blots were pre-hybridized in 50% formamide, 10% dextran
sulphate, 1 M sodium chloride, 1% SDS with 200 pg/ml carrier
DNA (denatured salmon sperm DNA). The cDNA probes were
labelled with 32P CTP using the Klenow DNA polymerase
reaction [39]. Blots were hybridized with the labelled probes
overnight at 42°C in the same pre-hybridization buffer before
being washed twice for 30 minutes at 42°C in 1 x SSC with 1%
SDS and twice at 42°C for 30 minutes in 0.lx SSC with 1%
SDS. The blots were exposed to XAR-5 film (Kodak) at —70°C.
Each blot contained a positive control using RNA obtained
from lipopolysaccharide (LPS)-stimulated human monocytes
and negative control with RNA from unstimulated quiescent or
proliferating mesangial cells as appropriate. The amount of
monocyte RNA used for Northern blots was reduced to 1 g
because the degree of cytokine gene expression was high, and
so hybridization with the tubulin probe was barely visible.
IL-6 and IL-8 assays
The IL-6 was measured using a specific capture ELISA assay
kit (Quantikine, R and D systems, Minneapolis, Minnesota,
USA) which has linear binding from 30 pg/mI to 2 ng/ml.
Preliminary experiments showed a 1:50 dilution of the test
samples was needed to ensure the results fell on the linear
portion of the standard curve, and so tissue culture superna-
tants from stimulated and unstimlated mesangial cells were
incubated at this dilution. The following IL-6 standards were
used: 2000 pg/mI, 1000 pg/ml, 500 pg/mI, 250 pg/mi, 125 pg/ml,
62.5 pg/mI, 31.3 pg/mI. To determine if the IL-6 was biologically
active, IL-6 was also assayed in selected samples using the
IL-6-dependent murine hybridorna cell line, B9 [40].
The IL-8 was assayed using a specific capture ELISA [41].
This assay has linear binding from 0.1 ng!ml to 100 ng/ml of
IL-8. Samples were incubated on ELISA plates at 1:20 after
preliminary experiments had shown this to be the appropriate
dilution. IL-8 standard concentrations were used in every assay
and a standard curve drawn from this. The biological activity of
IL-8 was assessed using the neutrophil shape change assay for
neutrophil chemotactic factors described by Haslett et al [42].
Mesangial cells were stimulated for three hours in serum-free
medium containing 10 ng!ml IL-i before the supernatant was
removed, the cells were washed in fresh medium and incubated
overnight in fresh serum-free medium without IL-i. In the
morning, aliquots of 50 l of this supernatant or a supernatant
from unstimulated mesangial cells were added to tubes contain-
Fig. 1. A. Lightmicrograph of confluent human mesangial cells show-
ing elongated cell morphology and multiple layers of cells (x250). B.
Human mesangial cells stained with anti-smooth muscle actin antibod-
ies, showing characteristic actin filament arrangement (x500).
ing 2 x i0 normal human neutrophils prepared by dextran
sedimentation, followed by discontinuous plasma PercollTM
(Pharmacia, UK) density gradient centrifugation [42]; cytospins
of these cells contained more than 98% pure neutrophils by
May-Giemsa. The neutrophils were fixed after 10 minutes at
37°C by adding 2% glutaraldehyde. Neutrophils exposed to
chemotactic factors developed pseudopodic and lamellapodic
cytoplasmic extensions, that is, they underwent "shape
change". The percentage of cells undergoing shape change was
calculated by direct counting and was related to the concentra-
tion of chemotactic factor. Polyclonal goat anti-IL-8 antibodies
were used to inhibit the shape change as a specificity control.
Results
Cell culture characteristics
Glomeruli adhered to tissue culture plates after three to four
days, cellular outgrowths were visible by five days and reached
confluence after six to ten days. The initial outgrowths were
heterogeneous, and included cells that bound anti-cytokeratin
antibodies and that took up Ac.LDL. After several passages the
cultures appeared uniform on light microscopy and consisted of
axially elongated cells which resembled smooth muscle cells
and grew in swirls. They were not contact inhibited and formed
the 'hills and valleys' morphology said to be characteristic of
mesangial cells [43, 44] (Fig. IA). Actin filaments running
longitudinally through the cells were seen in preparations
stained with anti-smooth muscle actin antibodies, an arrange-
ment typical of mesangial cells [45] (Fig. IB). Electronmicros-
copy showed that the cells had peripheral concentrations of
microfilaments, prominant Golgi apparatus and oval nuclei with
peripheral heterochromatin (Fig. 2). These features are typical
of mesangial cells [44] but not of fibroblasts. None of the cells
were stained with anti-cytokeratin antibodies, which identifies
epithelial cells, and none took up Ac.LDL. This therefore
demonstrates that the cultures were not contaminated with
endothelial cells or macrophages.
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Fig. 2. Electronmicrograph of a trypsinized mesangia! cell showing sparse organelles, abundant microfilaments (F), which in many cells were
arranged in plaques (inset), a prominent Golgi apparatus (G) and peripheral nuclear heterochromatin. In each case the bar represents 1 pm.
Stimulation of mesangial cells by hrIL-1f3
Proliferation. In six separate experiments, human recombi-
nant IL-1f3 in doses up to 1 g had no effect on mesangial cell
morphology or viability when added to quiescent cells growing
in medium containing 0,25% PPP, or to cycling cells maintained
in full growth medium. IL-i had equally little effect on incor-
poration of 3H thymidine by quiescent cells or cycling cells
(Fig. 3). Thus, there was no evidence that human recombinant
IL-1j3 was a competence or progression factor for human
mesangial cells when studied in this way.
Cytokine mRNA production. RNA was harvested from qui-
escent and cycling cells, either unstimulated, or incubated for
three hours with hrIL-1/3 in concentrations from 6 pg to 100
nglml. The RNA was then subjected to Northern analysis using
cDNA probes to tubulin, IL-6 and IL-8 sequentially. Messenger
RNA for IL-6 and IL-8 could not be detected either in quiescent
or proliferating cells in the absence of IL- 1/3, but mRNA for
both were induced with IL-1J3. This effect was found at con-
centrations as low as 6 pg/mI of IL-i f3 and appeared to be
0
Concentration of IL-i, ng/m/
0 1 5 10 100 1000
Fig. 3. Effect of increasing hrIL-1f3 concentration on proliferation of
human mesangial cells, quiescent cells in 0.25% PPP (solid bars) and
cycling cells in full growth medium containing 10% fetalbovine serum(hatched bars). Data from a representative experiment of 6.
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Fig. 4. Northern blot analysis of quiescent human mesangial cells
showing the same blot sequentially probed for tubulin, IL-si and IL-8.
Cellswere unstimulated (I) or stimulated for 3 hours with hrIL-1 /3 400
pg/mI (2), 1 ng/ml (3), 10 ng/ml (4), 500 nglml (5). Lipopolysaccharide(LPS) stimulated human monocyte RNA was used as the control (6).
Tubulin
Interleukin-6
Table 1. Effect of IL-1/3 and TNF on release of IL-6
culture supernatants
and
IL-6 IL-8
ng/ml
Untreated 4.5 2.0 3.0 2.0
IL-l/3 ng/ml
0.006 4.1 2.6 8.4 4.2
0.06 7.0 3.5 12.0 3.1
0.4 13.3 3.1 16.8 5.7
1.0 11.3 4.2 40.0 5.2
6.0 18.3 2.2 40.0 4.9
500 17.0 3.3 36.0 6.1
TNF ng/ml
10.0 5.2 3.5 2.9 1.1
50.0 4.45 3.2 5.4 1.0
100 11.75 2.5 8.27 0.73
1000 12.15 4.0 13.9 0.13
Results are expressed as mean standard error.
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FIg. 5. Northern blot analysis of quiescent human mesangial cells
showing the same blot sequentially probed for tubulin, IL-si and IL-8.
Cells were unstimulated (1) or stimulated with hrIL-I 10 ng/ml for I
hour (2), 2 hours (3), 3 hours (4), 8 hours (5).
greater when higher concentrations were used (Fig. 4). IL-1/3
did not influence the intensity of hybridization to the tubulin
probe. In two time course experiments, IL-6 and IL-8 mRNA
concentrations increased after incubation with IL-1p for one
hour, reached a maximum after three hours, but was still
greater than baseline at eight hours (Fig. 5). There was no
qualitative difference in results obtained with quiescent or
cycling cells.
The changes in steady state mRNA concentrations correlated
with cytokine secretion. Concentrations of IL-6 in supernatants
of quiescent unstimulated cells increased approximately four-
fold to over 18 ng/ml when the cells were stimulated for three
hours with appropriate concentrations of IL-1f3 (Table 1). The
results were very similar for IL-8 and again reflected the
changes in steady state mRNA on Northern blots. Unstimu-
Fig. 6. Effect of increasing hrTNF concentration on proliferation of
human mesangial cells, quiescent cells in 0.25% PPP (solid bars) and
cycling cells in full growth medium containing 10% fetal bovine serum
(hatched bars).
lated cells produced in the region of 3 to 4 ng/ml IL-8, which
rose to a maximum of 40 ng/ml after hrIL- 1/3 stimulation (Table
1).
Stimulation of mesangial cells by hrTNF
Proliferation. The capacity of TNF to stimulate human
mesangial cell proliferation was assessed in five experiments
using mesangial cells from different donors. TNF had no effect
on mesangial cell proliferation when used at concentrations of
50 nglml or less, even though these concentrations have been
reported to stimulate fibroblasts, endothelial cells and macro-
phages [46-SO]. However, incubation of mesangial cells with
TNF 100 ng/ml and 500 ng/ml caused a three-to fourfold
increase in DPM's, suggesting that high concentrations of TNF
induce proliferation of mesangial cells (Fig. 6); even so, the
increased proliferation is trivial when compared to that ob-
served in full growth medium. TNF neither enhanced nor
inhibited proliferation of cells in complete growth medium
containing 10% fetal calf serum (Fig. 6).
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Fig. 7. Northern blot analysis of quiescent human mesangia! cells
showing the same blot sequentially probed for tubulin and IL-6. Cells
were unstimulated (1) or stimulated for 3 hours with TNF 10 ng/ml (2),
100 ng/ml (3), 1 g/m1 (4). LPS stimulated human monocyte RNA was
used as a control (5).
Concentration of IL-6, ng/m/
Fig. 9. Effect of increasing hrIL-6 concentration on proliferation of
quiescent human mesangia! cells in medium containing 0.25% PPP.
Mesangial cells and other stimuli
Human recombinant IL-6 in concentrations of 100 pg to 250
ng/ml had no effect on mesangial cell proliferation (Fig. 9). It
had equally little effect of mRNA levels of IL-6 and IL-8 in six
separate experiments, even though there was strong hybridiza-
tion with tubulin mRNA. IL-6 at 10 nglml and 100 ng/ml did not
cause IL-8 release from the cultures. IL-8 was used to stimulate
mesangial cells in concentrations ranging from 10 to 20 ng/ml
but had no effect.
Bioactivity of IL-6 and IL-8
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Fig. 8. Northern blot analysis of quiescent human mesangial cells
showing the same blot sequentially probed for tubulin and IL-8. Cells
were unstimulated (I) or stimulated for 3 flours with hrTNF 1 nglml (2),
10 ng/ml (3), 50 ng/ml (4), 100 nglml (5), 1 sg/ml (6). LPS stimulated
human monocyte RNA was used as a control (7).
Steady state mRNA concentrations. The influence of TNF on
steady state mRNA concentrations was assessed using both
quiescent and proliferating cells. Messenger RNA for IL-6 and
IL-8 could not be detected in quiescent cells nor in cells after
three hours exposure TNF at concentrations from 1 to 50 nglml,
but was increased with TNF concentrations similar to those
required to induce proliferation; again tubulin gene expression
was unaffected. Similar results were obtained in three separate
experiments using cells from three different donors. This shows
that high concentrations of TNF specifically increase steady
state levels of mRNA for IL-6 (Fig. 7) and IL-8 (Fig. 8). The
time course was identical to that seen with IL-1f3 stimulation,
and the results were similar in cycling cells. Significant amounts
of IL-6 and IL-8 were produced at higher concentrations of
TNF and the most effective dose was 1 g/m1 TNF (Table 1).
The activity of mesangial cell-derived IL-6 was assessed from
proliferation of the IL-6-specific B9 murine hybridoma cell line.
The results show that quiescent human mesangial cells released
1.3 nglml of biologically active IL-6, and the concentration
increased to 5 nglml and 10 nglml after stimulation with IL- 1j3
(10 nglml) and TNF (1 pgIm1), respectively. Unstimulated
cycling cells released 5 ng/ml which increased to 50 ng/ml after
exposure to IL-1/3.
The ability of mesangial cell supernatants to induce neutro-
phil shape change was assessed in four separate experiments.
Supernatants from unstimulated quiescent cells did not induce
shape change, suggesting that they did not contain chemotactic
factors. However, supernatants from IL-1j3 stimulated mesan-
gial cells caused 90% shape change when used neat, and the
effect could be diluted out (Fig. 10). The ability of the superna-
tants to induce shape change was inhibited by a specific goat
anti-human IL-8 serum in four separate assays, but not by
antibodies to IL-1f3. The results of a representative experiment
are shown in Figure 10.
Discussion
This study was designed to examine the effects of TNF and
IL-1j3 on human mesangial cells because both cytokines have
powerful pro-inflammatory effects and are released in large
quantities by activated macrophages [51, 52]. They are found in
supernatants from inflamed glomeruli cultured in vitro [15, 16]
and could have important influences on the course of nephritis.
The effect of both cytokines on synthesis of IL-6 and IL-8 was
0 0.1 1 2 8 33 125 250
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studied. Interleukin-8 was chosen because it is one of a new
class of cytokines which are powerful neutrophil chemoattrac-
tants and thought to mediate some of the effects of IL-i and
TNF in vivo. Interleukin-6 was studied because of its possible
role in a negative feedback loop in controlling the effects of
TNF [12, 131.
Interleukin-l/3 stimulated synthesis of IL-8 by mesangial cells
when exposed to as little as 6 pg/mI. Increased steady state
mRNA concentrations for IL-8 were found one hour after
stimulation and persisted for at least 24 hours. This time course
is similar to that of IL-8 mRNA produced by IL- 1/3 stimulated
endothelial cells [53, 54] and contrasts with the more transient
changes in TNF mRNA [55]. The changes in IL-8 mRNA
concentration correspond to its release into the medium which
increased tenfold. The amounts released are likely to be bio-
logically important because concentrations as low as 100 pg/ml
induce neutrophil chemotaxis and lower concentrations still
induce lymphocyte chemotaxis [56]. However, macrophages
release much more IL-8 than mesangial cells. At higher con-
centrations IL-8 causes increased expression of neutrophil
CD1 lb/CD18 complex which mediates neutrophil adhesion
[57], the respiratory burst with generation of superoxide and
hydrogen peroxide, and exocytosis of neutrophil granules with
release of gelatinase, elastase, and f3-glucuronidase [58—60],
properties with important effects on inflammation.
Interleukin- 1/3 also stimulated IL-6 synthesis with the same
time course. Recently Topley et al [29] have shown that low
concentrations of hrIL-l/3 caused human mesangial cells to
release eicosanoids. Thus, human mesangial cells are exquis-
itely sensitive to IL-l/3. Previously, IL-l has been reported to
cause proliferation of both rat [6111 and human [26] mesangial
cells, and so at first sight it is surprising that neither Topley nor
ourselves were able to induce mesangial cells proliferation with
IL-l/3 even in concentrations manyfoid higher than those
needed for cytokine synthesis. However, there are differences
between our work and that previously reported. The only
human study in which IL-i was shown to cause mesangial cell
proliferation used IL-l purified from macrophage supernatants
[26]. Such preparations of IL-l are now known to contain
substantial amounts of other growth factors, including IL-6 [31]
and platelet-derived growth factor (PDGF), which could have
been responsible for proliferation rather than the IL-l itself.
However, studies by both Stahl et al [62] and Kester et al [63]
have shown that recombinant rat IL- 1 can induce proliferation
in rat mesangial cells when incubated with low concentrations
of serum. Rat mesangial cells have also been reported to release
increased amounts of IL-6 when stimulated to proliferate by
serum, and this effect is increased by exposure to LPS or TNF.
Rat mesangial cells have also been reported to proliferate in
response to IL-6 [23, 24] which lead to the suggestion that IL-6
was an autocrine growth factor. Potentially, IL-1f3 might induce
rat mesangial cells to proliferate indirectly through the effects of
IL-6 secretion, but experiments to test this have not been
reported. We were unable to induce human mesangial to
proliferate with hrIL-6 over a wide range of concentrations,
either in serum-free medium or in the presence of fetal calf
serum. It is too soon to be confident that the different effects of
cytokines on human and rat mesangial cell proliferation are due
to species variation or to differences in experimental design. We
used short proliferation assays to assess the effects of potential
growth factors after 48 hours, as these assays have been used
previously to demonstrate mesangial cell proliferation induced
by serum, PDGF and TNF. In contrast Horii et al [23] and Ruef
et al [24] both used longer assays in which DNA synthesis and
cell numbers were assessed after 72 hours. This, together with
differences in the concentrations of serum used, could explain
the discrepancies in the results.
The concentrations of IL- 1/3 required to stimulate mesangial
cells are well within the range attainable in vivo, but it is
uncertain whether this is true for TNF as concentrations greater
than 100 ng/ml were required. Serum TNF concentrations
rarely rise above 1 ng/ml even in septicemic patients [64], but
local TNF concentrations could be higher, especially adjacent
to an activated macrophage. Relatively high concentrations of
TNF are also required to stimulate endothelial cells in culture,
but macrophages are much more sensitive. Baud et al [27], who
showed that high concentrations of TNF stimulated eicosanoid
synthesis by rat mesangial cells, have reasoned that glomerular
concentrations might reach these levels.
In summary, this paper provides further evidence that IL-l/3
has powerful effects on human mesangial cells and that these
are likely to modulate glomerular inflammation.
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